Exane Derivatives Akebia Therapeutics, Inc. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Exane Derivatives holds 471 shares of AKBA stock, worth $687. This represents 0.0% of its overall portfolio holdings.
Number of Shares
471
Previous 471
-0.0%
Holding current value
$687
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding AKBA
# of Institutions
110Shares Held
55.3MCall Options Held
554KPut Options Held
246K-
Black Rock Inc. New York, NY11.6MShares$17 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.28MShares$13.5 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$8.39 Million11.5% of portfolio
-
Geode Capital Management, LLC Boston, MA4.54MShares$6.62 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA4.06MShares$5.93 Million0.01% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $268M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...